Timing of Immunotherapy Discontinuation Remains Challenging in Melanoma
Thomas Marron, MD, discusses the rationale for investigating immunotherapy discontinuation in patients with melanoma.
Thomas Marron, MD, an assistant professor of medicine, hematology and medical oncology at Mount Sinai Hospital, discusses the rationale for investigating immunotherapy discontinuation in patients with melanoma.
Marron and colleagues designed a clinical trial to address the challenge of when to stop immunotherapy. This is a hurdle in melanoma, as well as other histologies, because immunotherapies are very effective and more patients are achieving either durable remissions or disease stability. However, patients often remain on these treatments indefinitely.
In the case of nivolumab (Opdivo), the immunotherapeutic agent is given indefinitely, while pembrolizumab (Keytruda) is given for 2 years to patients with melanoma. Although these agents are inching researchers closer towards potentially curing the disease, it is unknown how much of the agent should be used or if physicians can be giving significantly less.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
